A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer …
J Casal Rubio, JL Firvida-Perez… - Cancer chemotherapy …, 2014 - Springer
Purpose This single arm, phase II study aims to evaluate the role of epidermal growth factor
receptor–tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
receptor–tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer …
JC Rubio, JL Fírvida-Pérez… - Cancer …, 2014 - pubmed.ncbi.nlm.nih.gov
Purpose This single arm, phase II study aims to evaluate the role of epidermal growth factor
receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
[PDF][PDF] A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non‑small‑cell lung cancer (NSCLC): a Galician Lung …
JC Rubio, JL Fírvida‑Pérez… - Cancer …, 2014 - grupogallegocancerdepulmon.org
Purpose This single arm, phase II study aims to evaluate the role of epidermal growth factor
receptor–tyrosinekinase inhibitor erlotinib as maintenance therapy following concurrent …
receptor–tyrosinekinase inhibitor erlotinib as maintenance therapy following concurrent …
[引用][C] A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung …
J CASAL RUBIO, JL FIRVIDA-PEREZ… - Cancer …, 2014 - pascal-francis.inist.fr
Author CASAL RUBIO, J 1; FIRVIDA-PEREZ, J. L 2; LOPEZ-VAZQUEZ, M. D 9; VAZQUEZ, S
8; LAZARO-QUINTELA, M 1; BARON-DUARTE, F. J 3; ALONSO-JAUDENES, G 4; …
8; LAZARO-QUINTELA, M 1; BARON-DUARTE, F. J 3; ALONSO-JAUDENES, G 4; …
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer …
JC Rubio, JL Fírvida-pérez… - Cancer …, 2014 - search.proquest.com
This single arm, phase II study aims to evaluate the role of epidermal growth factor receptor-
tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer …
J Casal Rubio, JL Fírvida-Pérez… - Cancer Chemotherapy …, 2014 - hero.epa.gov
PURPOSE: This single arm, phase II study aims to evaluate the role of epidermal growth
factor receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following …
factor receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following …
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer …
JC Rubio, JL Fírvida-Pérez, M Lázaro-Quintela… - Cancer Chemotherapy …, 2014 - infona.pl
Purpose This single arm, phase II study aims to evaluate the role of epidermal growth factor
receptor–tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
receptor–tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer …
J Casal Rubio, J Fírvida-Pérez… - Cancer …, 2014 - search.ebscohost.com
Purpose: This single arm, phase II study aims to evaluate the role of epidermal growth factor
receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
[PDF][PDF] A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non‑small‑cell lung cancer (NSCLC): a Galician Lung …
JC Rubio, JL Fírvida‑Pérez… - Cancer …, 2014 - grupogallegocancerdepulmon.org
Purpose This single arm, phase II study aims to evaluate the role of epidermal growth factor
receptor–tyrosinekinase inhibitor erlotinib as maintenance therapy following concurrent …
receptor–tyrosinekinase inhibitor erlotinib as maintenance therapy following concurrent …
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer …
JL Fírvida-Pérez, M Lázaro-Quintela… - Cancer …, 2013 - europepmc.org
Purpose This single arm, phase II study aims to evaluate the role of epidermal growth factor
receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …
receptor-tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …